Antioxidants break up the chains formed during the propagation process of the redox system by providing a hydrogen atom of an electron to the free radical and receiving the excess energy possessed by the activated molecule. The important role of dietary antioxidants in maintaining the integrity of living organisms is gaining ever-increasing recognition. New data are constantly gathered to show the role of oxidative stress and the involvement of reactive oxygen species and reactive nitrogen species in the pathogenesis of degenerative diseases. These diseases are associated with a disturbance in the necessary balance between the oxidation and the reduction status in blood and tissues, leading to oxidation of lipids, proteins and nucleic acids. Such oxidative damage is accompanied by changes in the macromolcular structure and function and by the manifestation of clinical disorders such as cardiovascular diseases and cancer. Hence, widespread research is being conducted aiming to investigate the possible effects and mechanisms of action of dietary antioxidants in these diseases. Antioxidants may exert their effect on biological systems by different mechanisms, including electron donation (as reducing agents), metal ion chelation (thereby eliminating potential free radicals), sparing of antioxidants (co-antioxidants) or by regulation of gene expression. Optimized content for mobile and hand-held devicesHTML pages have been optimized of mobile and other hand-held devices (such as iPad, Kindle, iPod) for faster browsing speed. Click on [Mobile Full text] from Table of Contents page. This is simple HTML version for faster download on mobiles (if viewed on desktop, it will be automatically redirected to full HTML version)

The potential of cell therapy in treating incurable and irreversible diseases has been proven to be safe and feasible with varying degrees of success in medical fraternity. In the past decade, there has been a steady increase in the development of advanced point-of-care cell processing technologies and intra-operative procedures that integrate autologous cell-based therapy with conventional surgical procedure in a single sitting, have emerged as an exciting approach in regenerative medicine and cell therapy field. Point-of-care (POC) cell processing devices are automatic, closed systems that allow rapid processing of whole tissue to the desired cell population at the patient's bedside, at an affordable cost. This observational study evaluates the safety and feasibility of a rapid point-of-care technology, the Res-Q™ 60 system used for processing bone marrow and/or peripheral blood intraoperatively for treating patients with various clinical indications who were administered the cell therapy product either as a standalone treatment or in conjunction with standard-of-care treatment. The data from 254 patients treated using either Bone Marrow Concentrate (BMC) or Platelet Rich Plasma (PRP) produced by Res-Q™ 60 devices was observed and analysed for device performance including cellularity, sterility and safety. The cellular output from Res-Q™ 60 BMC and PRP devices showed a significantly high MNC recovery of 71.35% ± 2.10 (SD) and platelet recovery of 78.3% ± 3.0 (SD), respectively. All the samples were sterile with no bacterial or fungal growth and all the patients tolerated the device output i.e. BMC or PRP well with no related adverse events (SAEs/ AEs). Therefore, the Res-Q™ 60 BMC and PRP devices were found to be safe, feasible and preliminary effective for autologous cellular therapy at the point-of-care.